Growth Metrics

Immuron (IMRN) Current Leases (2019 - 2022)

Immuron's quarterly Current Leases came in at $24622.4 in Q2 2022, up 55.99% year-on-year from $15784.6 in Q2 2021, and up 55.99% quarter-over-quarter from $15784.6 in Q2 2021.

Immuron has reported Current Leases for 4 years, with the latest figure at $24622.4 in Q2 2022.

  • For the quarter ending Q2 2022, Current Leases rose 55.99% year-over-year to $24622.4; the trailing twelve-month figure through Jun 2022 stood at $24622.4 (up 55.99% YoY), and the FY2022 full-year result was $24622.4, up 55.99% from the prior year.
  • Current Leases for Q2 2022 stood at $24622.4, up from $15784.6 in the prior quarter.
  • The five-year high for Current Leases was $41779.0 in Q4 2019, with the low at $15784.6 in Q2 2021.
  • Average Current Leases over 4 years is $27457.3, with a median of $26132.7 recorded in 2020.
  • Year-over-year, Current Leases sank 42.9% in 2021 and surged 55.99% in 2022.
  • Tracing IMRN's Current Leases over 4 years: stood at $41779.0 in 2019, then sank by 33.84% to $27643.0 in 2020, then slumped by 42.9% to $15784.6 in 2021, then surged by 55.99% to $24622.4 in 2022.
  • The last three Current Leases figures came in at $24622.4 (Q2 2022), $15784.6 (Q2 2021), and $27643.0 (Q2 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 83,991.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 7.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 720.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 45.66 Mn
10 Immuron 1.27 Bn 1.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 24,622.44
Jun 30, 2021 15,784.59
Jun 30, 2020 27,643.02
Dec 31, 2019 41,779.00